HanAll Biopharma is plunging by over 14% in early trading on April 3.


As of 9:13 a.m. on this day, HanAll Biopharma was trading at 36,550 won on the Korea Exchange, down 14.43% from the previous session.


[Market Focus] HanAll Biopharma Plunges Over 14% on Phase 3 Clinical Trial Failure View original image

This sharp drop is believed to be driven by reports that HanAll Biopharma's candidate treatment for thyroid eye disease (TED) failed to achieve statistical efficacy in Phase 3 clinical trials.



On April 2, HanAll Biopharma disclosed the main results of its Phase 3 clinical trial for the thyroid eye disease candidate drug "Batoclimab." The study targeted adult patients with active thyroid eye disease, administering a high dose (680mg) and a low dose (340mg) of Batoclimab for 12 weeks each, and measured the "proptosis response rate" at week 24 as the primary endpoint. However, statistical efficacy was not demonstrated.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing